Redhill Biopharma Ltd. (RDHL) SEC Filings — 2024
45 SEC filings for Redhill Biopharma Ltd. (RDHL) in 2024.
Filings
- RedHill's Opaganib Shows Radioprotective Activity in New Study — 6-K · Dec 10, 2024
- RedHill Biopharma Wins $8M Court Judgment — 6-K · Dec 2, 2024
- Redhill Biopharma Ltd. SC 13G/A Filing — SC 13G/A · Nov 14, 2024
- RedHill Biopharma to Present at World Congress of Gastroenterology — 6-K · Oct 28, 2024
- RedHill Biopharma Announces New Collaboration — 6-K · Oct 22, 2024
- RedHill Biopharma Files 6-K, Hints at U.S. Development — 6-K · Oct 15, 2024
- RedHill Biopharma Files 6-K, Announces Medi-Cal Deal — 6-K · Oct 1, 2024
- RedHill Biopharma Files 6-K on Coronavirus Update — 6-K · Sep 30, 2024
- RedHill Biopharma Shareholders Approve All Resolutions — 6-K · Sep 18, 2024
- RedHill Biopharma Adjourns Annual Shareholder Meeting — 6-K · Sep 17, 2024
- RedHill Biopharma Files 6-K on Talicia® Performance — 6-K · Sep 9, 2024
- RedHill Biopharma Files 6-K, Mentions Press Release — 6-K · Sep 5, 2024
- RedHill Biopharma Files 6-K, Incorporates Press Release — 6-K · Sep 3, 2024
- RedHill Biopharma Files 6-K, Details H1 2024 Performance — 6-K · Aug 29, 2024
- RedHill Biopharma's Opaganib Gets FDA Orphan Drug Designation — 6-K · Aug 26, 2024
- RedHill Biopharma Launches Talicia in UAE — 6-K · Aug 21, 2024
- RedHill Biopharma Obesity Study Shows Positive Results — 6-K · Aug 19, 2024
- RedHill Biopharma Files 6-K with SEC — 6-K · Aug 16, 2024
- RedHill Biopharma Ltd. Files Notice for Annual Shareholder Meeting — 6-K · Aug 13, 2024
- RedHill Biopharma Schedules Annual General Meeting — 6-K · Aug 6, 2024
- RedHill Biopharma Reports Positive Phase 2 Study Results — 6-K · Aug 1, 2024
- RedHill Biopharma Ltd. Files Form 6-K — 6-K · Jul 22, 2024
- RedHill Biopharma Terminates T-Cure Bio Agreement — 6-K · Jul 9, 2024
- RedHill Biopharma Director Resigns — 6-K · Jun 6, 2024
- RedHill Biopharma Secures New US Patent for Talicia — 6-K · Jun 3, 2024
- RedHill Sells Talicia Rights for $10M Upfront — 6-K · May 6, 2024
- RedHill Biopharma Enrolls First Patient in COVID-19 Study — 6-K · Apr 24, 2024
- RedHill Biopharma Files 2023 Results 6-K — 6-K · Apr 8, 2024
- RedHill Biopharma Ltd. Files 20-F Annual Report for Fiscal Year 2023 — 20-F · Apr 8, 2024
- RedHill Biopharma Closes $10M Direct Offering — 6-K · Apr 4, 2024
- RedHill Biopharma Closes $15M Private Placement — 6-K · Apr 3, 2024
- RedHill Biopharma Announces $1.25M Direct Offering — 6-K · Apr 2, 2024
- RedHill Biopharma Holds Shareholder Meeting — 6-K · Mar 21, 2024
- RedHill Biopharma Adjourns Shareholder Meeting — 6-K · Mar 20, 2024
- RedHill Sells Talicia Rights for $10M — 6-K · Mar 14, 2024
- RedHill Biopharma Gets New USPTO Patent for COVID-19 Drug — 6-K · Mar 11, 2024
- RedHill's Opaganib Selected for NIAID COVID-19 Trial — 6-K · Mar 5, 2024
- RedHill Biopharma Files 6-K on Opaganib Progress — 6-K · Feb 20, 2024
- RedHill Biopharma Files 6-K for Extraordinary General Meeting — 6-K · Feb 13, 2024
- Intracoastal Capital Takes 9.99% Stake in RedHill Biopharma — SC 13G · Feb 2, 2024
- CVI Investments Takes 700M Share Stake in RedHill Biopharma — SC 13G · Feb 1, 2024
- RedHill Biopharma Preps for Potential Securities Offering — 6-K · Jan 26, 2024
- RedHill Secures Talicia® Patent Extension to 2042 for H. pylori Treatment — 6-K · Jan 25, 2024
- Empery Asset Management Divests Sole Voting Power in RedHill Biopharma — SC 13G/A · Jan 8, 2024
- Sabby Volatility Exits RedHill Biopharma, Now Owns 0% of ADSs — SC 13G/A · Jan 2, 2024